Maze Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGMaze Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 40), showing significant lag compared to the market leaders. Earnings growth of 40% provides fundamental context to the price action. However, with RSI at 77, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $26.43 | +22.41% | ABOVE |
| 50 SMA | $26.10 | +23.97% | ABOVE |
| 100 SMA | $32.91 | -1.71% | BELOW |
| 150 SMA | $35.85 | -9.76% | BELOW |
| 200 SMA | $34.30 | -5.68% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is MAZE in an uptrend right now?
MAZE has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is MAZE overbought or oversold?
MAZE's RSI (14) is 77. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is MAZE outperforming the market?
MAZE has a Relative Strength (RS) Rating of 40 out of 99. MAZE is currently lagging the broader market.
Where is MAZE in its 52-week range?
MAZE is trading at $32.35, which is 60% of its 52-week high ($53.65) and 50% above its 52-week low ($11.34).
How volatile is MAZE?
MAZE has a Beta of 1.01 and 52-week volatility of 87%. It's more volatile than the S&P 500 - expect bigger swings.